Higher Revenues Surpass Expectations, but EPS Falls Short


Higher Revenues Surpass Expectations, but EPS Falls Short

Creative Medical Technology Holdings (NASDAQ: CELZ) recently released its full year 2023 results. The company’s revenue exceeded analyst expectations by 50%, although earnings per share (EPS) fell short by 2.2%. Looking ahead, revenue is forecasted to grow by an average of 61% per year over the next three years, outpacing the 17% growth forecast for the Biotechs industry in the US.

In the American Biotechs industry, Creative Medical Technology Holdings’ shares are down 3.2% from a week ago. It’s important for investors to consider the risks associated with investing in this company. There are three warning signs identified with Creative Medical Technology Holdings, at least two of which are significant. Understanding these risks should be a part of the investment process.

If you have feedback on this article or are concerned about the content, you can get in touch with us directly or email the editorial team at simplywallst.com. This article is general in nature and provides commentary based on historical data and analyst forecasts using an unbiased methodology. It is not intended to be financial advice or a recommendation to buy or sell any stock. Our analysis aims to provide long-term focused insights that are driven by fundamental data. Note that our analysis may not include the latest price-sensitive company announcements or qualitative material. Simply Wall St does not have a position in any stocks mentioned.

Leave a Reply